📰 Development Partnership News
Page 23 - Development Partnership News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Partnership. Real-time updates on events, politics, business and more.
November 3, 2023
Treatment with oral zoliflodacin was found to be noninferior to ceftriaxone and oral azithromycin for the treatment of gonorrhea infection.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.
November 3, 2023
Gonorrhea, the second most common STI in the U.S., has developed resistance to all antibiotics used to treat it, except for one last recommended therapy.